Alnylam Pharmaceuticals Stock News

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Bank of America Securities 2020 Napa Biophar

Alnylam's (ALNY) share price rises more than 14% year to date based on pipeline developments.

Ever wondered how to buy shares in Regeneron Pharmaceuticals in Australia? We explain how and compare the best share trading platforms.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview a

The

AlphaCrest Capital Management LLC cut its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 58.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exc

THE COMMON cold could help provide immunity to the deadly coronavirus for up to 17 years, a new study has found. It comes as the UK confirmed an additional 202 coronavirus deaths over the past 24 hour

AKCA is a highly uninteresting stock - perhaps just the kind we need in these times. It has two approved products and a long pipeline in rare diseases. AKCA is

The company plans to test REGN-COV2 - consisting of the SARS-CoV-2-specific antibodies REGN10933 and REGN10987 - in four populations, including infected patients and uninfected people at high risk of

Scopus BioPharma has licensed a gene-silencing drug from California’s City of Hope hospital that is due to start

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that pivotal results from the ENVISION Phase 3 study of givosiran, an RNAi therapeutic targeting am

Economic optimism has broadened the market rally. Small caps had lagged significantly and are now catching-up as they narrow the performance gap. The Federal Re

Experts suspect – but there is no proof – that those who have developed antibodies will have immunity. The implications could be wide-ranging

Sorrento announced a positive update on COVIDTRAP. Blueprint announced a strong trial performance. Alnylam's Lumasiran trial in phase 3 provides an encouraging